Summit’s C. diff benefits for ridinilazole continue with early, sustained effect on quality of life

Summit now has quality-of-life data for its ridinilazole to treat Clostridium difficile infections showing benefits over SOC that could help HTAs such as NICE as they develop new value assessment frameworks to capture the benefits of antibiotics.

On Thursday, Summit Therapeutics plc (LSE:SUMM; NASDAQ:SMMT) reported patient-reported outcomes data from the Phase II CoDIFy trial that showed that ridinilazole had a statistically significant improvement in quality of life from baseline starting at day five following treatment (p=0.008). It took until day 12 for the mean changes from baseline in quality of life (QOL) to reach statistical significance in the vancomycin arm...